# Yizun Biomedical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/yizun-biomedical

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.stphimed.com
- Total disclosed funding: $14M
- Latest round: Series A (Apr 15, 2024)
- Investors on record: 9

## About

Established in 2018 and based in Hangzhou, China, Yizun Biomedical is dedicated to developing innovative cell therapies for cancer treatment. The company originated from the Fred Hutchinson Cancer Research Center and the University of Washington and was officially founded in Shanghai the same year. Yizun has established a significant presence with a research and development base in Hangzhou and has expanded its operations with a GMP-standard production facility. Under the leadership of the founder Dr. Liu Lingfeng, the company has built a team of experts with extensive experience in the field. Yizun has forged strategic partnerships with renowned institutions such as Zhejiang University School of Medicine Affiliated First Hospital and Fujian Provincial Tumor Hospital, among others, to advance its clinical research and development efforts. In April 2024, it raised approximately CNY 100 million in series A+ funding.

The company specializes in the development of cell therapies based on its proprietary CNK-T, VAC-T, and U-T technology platforms. The CNK-T platform is designed to overcome the immune suppression barrier in solid tumors, while VAC-T enhances the internalization and presentation of tumor or viral antigens. The U-T platform ensures the safety and timeliness of allogeneic cell therapy, enabling scaling production and standardized treatment. These therapies are aimed at treating a wide range of solid and blood tumors, as well as autoimmune diseases and viral infections.

The company generates revenue by providing innovative cell therapy products and services, focusing on the development and potential commercialization of treatments for various types of cancer and immune-related conditions.

The company plan to use the series A+ funding to advance its clinical research, regulatory submissions, and team expansion, with a strategic focus on both the Chinese and American markets.

## Funding rounds

- Series A, Apr 15, 2024, $14M — TigerYeah Capital, Hangzhou Gaoxin Technology Venture, Tailong VC
- Series A, Jan 11, 2022 — TEDA Venture Capital, VMS Asset Management, Panacea Venture, Shenzhen Capital Real Estate Fund, Tao Capital, Tasly Capital
- Angel, Oct 26, 2018 — Shenzhen Capital Real Estate Fund

## Investors

- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Angel, Series A
- TEDA Venture Capital (https://capitalatlas.ai/funds/teda-venture-capital) — Series A
- VMS Asset Management (https://capitalatlas.ai/funds/vms-asset-management) — Series A
- Panacea Venture (https://capitalatlas.ai/funds/panacea-venture) — Series A
- Tao Capital (https://capitalatlas.ai/funds/tao-capital) — Series A
- Tasly Capital — Series A
- TigerYeah Capital (https://capitalatlas.ai/funds/tigeryeah-capital) — Series A
- Hangzhou Gaoxin Technology Venture — Series A
- Tailong VC (https://capitalatlas.ai/funds/tailong-vc) — Series A